Saturday 17 October 2026
Export PYXS’s income statement to Excel — free account
Pyxis Oncology, Inc.
PYXS Healthcare Biotechnology
Pyxis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.9 million, down 14.2% from fiscal 2024. In the quarter to June 2026, EPS fell 33.3% and free cash flow fell 5.46%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.68
0.12
−6.67%
Follow PYXS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 7.90 | 1.10 | 1.34 | 1.49 | 0.83 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 19.00 | 11.50 | 6.92 | 6.85 | 5.55 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 56 | 75 | 50 | 44 | 56 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.37 | 0.25 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 16 | 14 | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 97.06 | 82.77 | |||||
| EBT | — | — | — | (3) | (13) | (76) | (121) | (74) | (79) | (78) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (492.35) | (564.55) | |||||
| Net income | — | 0 | — | (3) | (13) | (76) | (121) | (74) | (77) | (80) | |||||
| Depreciation | — | — | — | — | 0 | 1 | 1 | (3) | (3) | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.22 | ||||
| Earnings | — | — | — | (0.08) | (12.44) | (8.95) | (3.65) | (1.85) | (1.32) | (1.28) | |||||
| Cash flow | — | — | — | (0.07) | (9.78) | (4.16) | (2.70) | (1.77) | (0.99) | (1.02) | |||||
| Capex | — | — | — | 0.00 | (1.44) | (0.06) | (0.19) | (0.17) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.07) | (11.22) | (4.22) | (2.90) | (1.94) | (0.99) | (1.02) | |||||
| Book value | — | — | — | 0.56 | (15.17) | 30.77 | 4.87 | 3.15 | 2.07 | 0.86 | |||||
| Shares, m | — | — | — | 34 | 1 | 8 | 33 | 40 | 58 | 62 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.76 | 1.34 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.64 | (0.05) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (2) | (10) | (35) | (89) | (71) | (58) | (64) | ||||
| Capex | — | — | — | — | (1) | (1) | (6) | (7) | 0 | 0 | |||||
| Free cash flow | — | — | — | (2) | (12) | (36) | (96) | (77) | (58) | (64) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 19 | 4 | 260 | 155 | 99 | 115 | 51 | ||||
| Total debt | — | — | — | 0 | 1 | 0 | 19 | — | — | — | |||||
| Net debt | — | — | — | (20) | (8) | (276) | (181) | (121) | (128) | (68) | |||||
| Shareholders’ equity | — | — | — | 19 | (16) | 261 | 161 | 126 | 121 | 53 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (27.99) | (85.64) | (52.37) | (49.13) | (38.32) | (46.74) | (64.03) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (1,041.19) | 0.00 | 0.00 | |||||
| ROE | — | — | — | 29.94 | 138.54 | (61.85) | (57.19) | (51.51) | (62.75) | (91.43) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Dec 2025
Charts ten years each
Pyxis Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics, Inc. | $220.1M | — (loss-making) | — (loss-making) | −99.83% (below 0%: shrinking) | n/m | +32.19% (above 0%: growing) | 100.00% | 0.00% | Compare |
| PLX Protalix BioTherapeutics, Inc. | $217.5M | 10.9× | 10.2× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| CAMP CAMP4 Therapeutics Corporation | $216.5M | — (loss-making) | — (loss-making) | +18.84% (above 0%: growing) | n/m | −23.90% (below 0%: shrinking) | 100.00% | (752.11%) | Compare |
| PYXS Pyxis Oncology, Inc. | $215.3M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | |
| EVMN Evommune Inc. | $215.2M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MGNX MacroGenics, Inc. | $214.7M | — (loss-making) | — (loss-making) | +377.97% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| ALEC Alector, Inc. | $213.3M | — (loss-making) | — (loss-making) | −57.84% (below 0%: shrinking) | n/m | +30.19% (above 0%: growing) | 100.00% | (734.73%) | Compare |
| IFRX InflaRx N.V. | $212.2M | — (loss-making) | — (loss-making) | −128.93% (below 0%: shrinking) | n/m | +69.33% (above 0%: growing) | 14,029.95% | 0.00% | Compare |
| ZNTL Zentalis Pharmaceuticals, Inc. | $212.1M | — (loss-making) | — (loss-making) | — | n/m | −9.06% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $214.9M | — | — | −19.50% | — | +17.33% | 100.00% | 0.00% |
Pyxis Oncology, Inc. (PYXS) key facts
- Concern: Pyxis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.9 million, down 14.2% from fiscal 2024.
- Pyxis Oncology, Inc. (PYXS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PYXS traded at $1.68, a market capitalization of $215.3 million.
- Return on equity was −91.4% and debt-to-equity 0.00.
- Its Altman Z-score is −7.88 (distress zone) for fiscal 2025.